Member Info for MY21

Today’s RNS highlights clearly that the CEO & CFO based in London have been at best casual and at worst negligent in the last 2 years as we have had the following issues:
1. Two Brazilian General Managers misappropriating funds
2. Production Targets reduced for 2021 in Q3 2020
3. Huge Capital Raise to finance debt repayment for reminder of acquisition of Coringa
4. Today’s catalogue of problems which should have been anticipated and Market guided earlier.
My expectation is : The High Gold Price is saving the CEO from falling in his Sword at the moment and the large institutional shareholders in #SRB are probably keeping their powder dry given real inflation is 7-8% and if they need to do any thing : Ir takes time to replace the CEO or funding a Company wishing to take out #SRB.
One more unexpected surprise & CEO is gone IMHO.
It is a great shame as the company has above average assets with highly desirable grades but the management has been pedestrian in the last 2 years.
Good manager T teams earn their money in tough times ( Like the last 2 years ) otherwise most can run companies well in normal times.

HEMO Interview released today:
Key highlights for me were as follows:
1. Vlad is much more relaxed and assured than ever-I have met him 3 times in the last 4 years.
2. CDX collaboration with Global Pharma has been going for 3 years ( Where we have had access to their IP, facilities and their expertise and now finished in early Jan 2021 & we are now working on how to develop CDX Neutralising Antibody in remaining part of 2021
3. HEMO CAR T Therapy-PENN University chose us as they loved our data and research. We are half-way though our collaboration and the focus is on filing IND later this year and plan for manufacturing CAR T going forward.
4. Humanised Mice is used in multiple JVs including with J&J and Eli Lilly
-Humanised Mice gives us opportunity to validate CAR T and develop our new CBR Platform amongst other things
-Decided against getting an IP for Humanised Mice as it is impossible to enforce infringement by other third parties due to size of our company
-Humanised Mice is effectively our R & D tool which we utilise in collaboration by customise it to the requirements of the relevant Partner. This way no Partner ever can see what our secret weapon ; Humanised Mice is working
5. Vlad acknowledged when prompted by Zak that #HEMO is an R & D company now & is transitioning to become a Clinical Stage Company by the end of this year.
6. He stated he can not talk about everything now but there will be news coming out on various activities throughout 2021.

Key Milestones to watch out for the remainder of 2021:
a. Development of CDX Antibody
b. File IND & go into Clinical Trials on CAR T by end of 2021.
c. Significant update on CBR Platform which can address in due course :
-Treatment of respiratory diseases like COVID & different variants
-Prevention of various Cancers
The most important comment for me was when he said :
Key inflection point for the company will be CLINICAL Proof of Concept of our Product Candidates-As this means we will no longer be a £30m and/or $50m Business-10 minutes Google search will help you work out what the real value should be he suggested to Zak.

In summary, an excellent and assured overview of what the company does, key priorities in 2021 and what he hopes to deliver in 2021 to enhance shareholder value.

https://twitter.com/paul_rx8/status/1278371852159782917

Just watched the UKGov Testing webinar.

If you think covid19 is a bubble for the diagnostic company’s think again.

Testing is here to stay in ever increasing numbers. From the work place, care homes, GPs, Hospital etc.

#GDR #NCYT #ODX all have big roles to play. https://twitter.com/jimbethell/status/1270663782663163905…

https://twitter.com/messages/media/1270708934140100615

https://twitter.com/keya5000/status/1270708973075742720

See presentation released on this chat forum early Saturday morning by Orgenesis who are collaborating with HEMO as I stated in my post.

Orgenesis, who signed a commercial deal with Hemo in 2018 to develop and sell their HuPHEC cells and mice released market sensitive information late friday early Saturday.

Hemogenyx will have to release an RNS today or tomorrow at worst case scenario.

Orgenesis presentation highlighted the following :

. Hemogenyx mice (appear to be commercially ready)

. Hemogenyx mice used for covid treatment identification and testing

. Hemogenyx mice used for covid vaccine identification and testing

. Hemogenyx Hu-PHEC cells being described as Breakthrough in cloning pathogen antibodies for use against virus x!! (the big one)

The current share price is perfectly reasonable as it is going through a Consolidation phase after a 350% increase in the last 3 Trading Days.
Unless you are a Day Trader; there is every prospect of further respectable gain in company's valuation based on its Cancer research collaboration as well as its new COVID19 research in the coming weeks.
Should we get any material news in respect of either of the above; it is NOT unrealistic to assume a substantial Re-rating especially as COVID-19 Competitor Set have risen sharply in the last 8-12 weeks

Good morning All
My research indicates that the following warrants were outstanding as at 18th Feb 2020:
69,067 at exercise price of 1500 pence Expiry: 11/04/2020
383,333 at exercise price of 200pence Expiry: 19/01/2022 & finally 1,974,000 at exercise price of 100 pence with expiry on 05/06/2021
Source : BRD

Analysts at Berenberg revised their target price for miner Petra Diamonds slightly higher on Tuesday following a first half of trading which they described as a "mixed bag".
With net debt of $596m, broadly flat but slightly above Berenberg's estimates of $577m, the German bank expects Petra to deleverage in the second half.

While Berenberg acknowledged that a pit wall failure occurred at Petra's Williamson project in January, with 1.3mt of material falling into the pit, would likely lead to an increased capex throughout 2020 - as mining had now moved to the north-west area of the pit and guidance remaining unchanged following a strong start to the year, the analysts said that with cash relating to Williamson mostly staying in Tanzania, they do not expect "a major impact" to the group's cash management.

The analysts also pointed out that Petra saw increased market stability towards the end of the December quarter, and highlighted that management noted that demand "continued to improve" post-period end as the midstream replenished inventory.

Berenberg reiterated its 'hold' rating on Petra and nudged its price target on the group up to 10.0p from 9.0p in anticipation of higher prices in the third quarter of the miner's 2020 financial year and an improved long-term cost profile.

Offsetting those factors were the likely increased capital spending at Williamson and the broker's forecasts for a slower improvement in mix at Petra's Finsch.

Good afternoon Ladies & Gents
Please see below FYI only :
https://twitter.com/my21_oracle/status/1186216852877402113?s=21

Good morning All Try this in your browser and you should see it http://www.lse.co.uk/LiveSharePrice.asp?shareprice=ABM&share=african_battery

As I have been here longer than nearly all of you; I refrain from being either negative or positive based on any subjective analysis on the outlook for Sula’s future and it’s share price. I merely ask a simple and objective question; How long does it take for the new Geologist interpret the data? I think we have now been waiting for 12 weeks? My Geo friends in England tell me it should take a maximum of 2/3 weeks. Are the Board Of Directors Of Sula really think Retail Investors in their company lack intellect or logic? Long live intellect and logic is my polite message to the Sula’s BOD.

Sula Iron & Gold (SULA LN)# Sula Iron & Gold (SULA LN) has provided a corporate update. Structural interpretation work following the recent drilling programme and soil sampling is ongoing. The results of this analysis will aid in identifying the most appropriate next steps for development and management is of the opinion that finding a JV or farm in partner may be the most advantageous way of developing the Ferensola project. The board have also indicated that it intends to expand SULA’s asset base and is considering opportunities in this regard. We reiterate our Speculative Buy recommendation and 1.2p target price.

Is only a further evidence of new management having inherited a conpany which lacked funds and direction almost 12 months ago managing to achieve the impossible by: 1. Raise substantial funds in the last 12 months 2. Waste a significant proportion of it on targeting other zones with negligible Assay Results 3. Now decide to review all Assays in hand and decide the way forward by the year end & 4. Undertake a Darwin Style Fundraising to finally kill off any recovery in the share price for nearly ever In conclusion; all shareholders including current management who invested their own money nearly 12 months ago have lost money as they are sitting on huge paper losses if they have not sold like me. No wonder Aim has a bad reputation amongst many investors in U.K. and abroad I could list at least 50 Miners who have done what Sula has done in the last 5 years by aimlessly raising cash for exploration without an annual coherent strategy and a tactical plan to deliver this stated strategy. On a human level; the past and current directors of Sula should be extremely sorry and embarrassed for misleading investors and resulting in many if not nearly all of them losing substantial amount of their hard earned post tax investment in this company.

Sula Iron & Gold (SULA LN)# Sula Iron & Gold (SULA LN) has announced the departure of Howard Baker as Non-Executive Technical Director. In place, John Gould, who is a geologist and Partner at Madini (SULA’s technical advisors) will fulfil this role alongside and experienced South African based geologist who has significant experience of Archean greenstone gold deposits. The pair will continue the ongoing structural interpretation work at Ferensola. We reiterate our Speculative Buy recommendation and target price of 1.2p

Sula Iron & Gold (SULA LN)# Sula Iron & Gold (SULA LN) has announced further results from its 5,185m Phase 3 drilling campaign including high grade intercepts at the new TZ4 target as well as at Sanama Hill. These are the final results from this programme. The results at TZ4 included 1.2m at 19.3g/t Au from a depth of 287m which follows on from the earlier result of 5.2g/t Au from hole FDD021 around 600m away. We note, however, that SULA has stated that the structural orientation of these holes is different which indicates multiple controls and that as at Sanama Hill the structural geology is complex. This is something that management is putting significant effort into understanding and will help with future drill targeting and understanding the potential of the mineralisation discovered to date. Additional drill results were from Sanama Hill and also included encouraging high grades such as 8.6g/t Au over 2m from 134m deep as well as 7.5g/t Au in near surface oxide ore from 31m deep. The drilling campaign has provided robust results including high grade intercepts such as these although now the focus at Sanama Hill will be on low cost analysis of the data with a particular focus on structural geology. Soil sampling across 8 of 19 identified targets has demonstrated multiple zones with anomalous gold values. One of these includes a new gold target to the northeast of Sanama Hill yielding anomalous gold grades, underpinning the company’s view that there is further potential for gold targets beyond those that have been tested to date. We reiterate our Speculative Buy recommendation and 1.2p target price.

I hope you are well. I think you and I are in agreement on the timing of more funds: My guess is April 2018 I also find this disturbing in the RNS: e share price appreciation. The Investors have agreed to a lock up over the Subscription Shares until 13 September 2017 and have undertaken that neither they, nor any of their investors or affiliates will hold any short position in the Company's issued share capital. So much for the alignment of these investors interest with the company. Either have a Lock up agreement which is credible or have none. A lock up Agreement if merely 23 days is meaningless

I trust you are well mate and life is good despite the downward spiral in Sula's share price at the moment